Ronghao Zheng1, Alex Gonzalez2, Jing Yue3, Xiaolin Wu4, Ming Qiu5, Lin Gui5, Songbai Zhu5, Li Huang5. 1. Department of Nephrology, Rheumatology, and Immunology, Maternal and Child Health Hospital of Hubei Province, Wuhan, People's Republic of China; Department of Pediatrics, University of California, San Diego, California. 2. Department of Pediatrics, University of California, San Diego, California; Biology undergraduate Program, University of California, San Diego, California. 3. Emergency Department, Maternal and Child Health Hospital of Hubei Province, Wuhan, People's Republic of China. 4. Department of Nephrology, Rheumatology, and Immunology, Maternal and Child Health Hospital of Hubei Province, Wuhan, People's Republic of China. Electronic address: hbfyetsbfsmyk2013@126.com. 5. Department of Nephrology, Rheumatology, and Immunology, Maternal and Child Health Hospital of Hubei Province, Wuhan, People's Republic of China.
Abstract
BACKGROUND: The efficacy of vitamin D supplementation in patients with systemic lupus erythematosus (SLE) remains uncertain. This meta-analysis aimed to systematically evaluate the efficacy and safety of vitamin D supplementation in patients with SLE. MATERIALS AND METHODS: Randomized controlled trials (RCTs) were searched in PubMed, Embase, Cochrane CENTRAL and Web of Science databases. The retrieved studies were subjected to meta-analysis using the fixed-effect or random-effect model. RESULTS: Five eligible RCTs enrolling 490 participants were included. Compared to the placebo treatment, vitamin D supplementation significantly increased the level of serum 25-hydroxyvitamin D (25(OH)D) (5 trials, 490 participants: standard mean difference (SMD) = 2.072, 95% CI: 1.078-3.066, P < 0.001). The pooled result from 2 RCTs showed that vitamin D supplementation decreased the fatigue severity scale scores in patients with SLE (2 trials, 79 participants: SMD = -1.179, 95% CI: -1.897 to -0.460, P = 0.001). The SLE disease activity index scores and positivity of anti-double-stranded DNA antibodies (anti-dsDNA) did not differ significantly (4 trials, 223 participants: SMD = -0.507, 95% CI: -1.055-0.041, P = 0.070; 3 trials, 361 participants: Risk ratio = 0.880, 95% CI: 0.734-1.054, P = 0.165) between the vitamin D supplementation group and the placebo treatment group. None of the included studies reported severe adverse events associated with vitamin D supplementation. CONCLUSIONS: This meta-analysis suggested that vitamin D supplementation is effective in increasing the serum 25(OH)D levels, may improve fatigue, and is well-tolerated in patients with SLE, however, it does not seem to have significant effects in decreasing the positivity of anti-dsDNA and disease activity.
BACKGROUND: The efficacy of vitamin D supplementation in patients with systemic lupus erythematosus (SLE) remains uncertain. This meta-analysis aimed to systematically evaluate the efficacy and safety of vitamin D supplementation in patients with SLE. MATERIALS AND METHODS: Randomized controlled trials (RCTs) were searched in PubMed, Embase, Cochrane CENTRAL and Web of Science databases. The retrieved studies were subjected to meta-analysis using the fixed-effect or random-effect model. RESULTS: Five eligible RCTs enrolling 490 participants were included. Compared to the placebo treatment, vitamin D supplementation significantly increased the level of serum 25-hydroxyvitamin D (25(OH)D) (5 trials, 490 participants: standard mean difference (SMD) = 2.072, 95% CI: 1.078-3.066, P < 0.001). The pooled result from 2 RCTs showed that vitamin D supplementation decreased the fatigue severity scale scores in patients with SLE (2 trials, 79 participants: SMD = -1.179, 95% CI: -1.897 to -0.460, P = 0.001). The SLE disease activity index scores and positivity of anti-double-stranded DNA antibodies (anti-dsDNA) did not differ significantly (4 trials, 223 participants: SMD = -0.507, 95% CI: -1.055-0.041, P = 0.070; 3 trials, 361 participants: Risk ratio = 0.880, 95% CI: 0.734-1.054, P = 0.165) between the vitamin D supplementation group and the placebo treatment group. None of the included studies reported severe adverse events associated with vitamin D supplementation. CONCLUSIONS: This meta-analysis suggested that vitamin D supplementation is effective in increasing the serum 25(OH)D levels, may improve fatigue, and is well-tolerated in patients with SLE, however, it does not seem to have significant effects in decreasing the positivity of anti-dsDNA and disease activity.
Authors: Shayan A Irfan; Abid A Ali; Naqiha Shabbir; Hina Altaf; Ali Ahmed; Jafrikh Thamara Kunnath; Naga Vijaya L Divya Boorle; April K Miguel; Chia Chi Loh; Nikhila Gandrakota; Mirza M Ali Baig Journal: Cureus Date: 2022-06-13
Authors: Francisco Javier Turrubiates-Hernández; Gabriela Athziri Sánchez-Zuno; Guillermo González-Estevez; Jorge Hernández-Bello; Gabriela Macedo-Ojeda; José Francisco Muñoz-Valle Journal: Int J Mol Med Date: 2021-02-04 Impact factor: 4.101
Authors: Louise R Durrant; Giselda Bucca; Andrew Hesketh; Carla Möller-Levet; Laura Tripkovic; Huihai Wu; Kathryn H Hart; John C Mathers; Ruan M Elliott; Susan A Lanham-New; Colin P Smith Journal: Front Immunol Date: 2022-02-24 Impact factor: 7.561
Authors: Maria G Grammatikopoulou; Konstantinos Gkiouras; Meletios P Nigdelis; Dimitrios P Bogdanos; Dimitrios G Goulis Journal: Nutrients Date: 2020-03-04 Impact factor: 5.717